

## CURRICULUM VITAE

### **PART I: General Information**

**DATE PREPARED:** September 2008

**Name:** Aram Francis Hezel

**Office Address:** Massachusetts General Hospital Cancer Center  
Division of Hematology/Oncology  
55 Fruit Street, Professional Office Building, Suite 236  
Boston, MA 02114

### **Education:**

1995 B.A. Vassar College, Poughkeepsie, NY  
2000 M.D. State University of New York at Buffalo School of Medicine, Buffalo, NY

### **Postdoctoral Clinical Training:**

Internship and Residency:

2000-2001 Intern in Medicine, Beth Israel Deaconess Medical Center  
2001-2002 Junior Assistant Resident, Internal Medicine, Beth Israel Deaconess Medical Center  
2002-2003 Senior Assistant Resident, Internal Medicine, Beth Israel Deaconess Medical Center

### **Clinical and Research Fellowships:**

2000-2003 Clinical Fellow in Medicine, Harvard Medical School, Boston, MA  
2003-2006 Fellow in Hematology/Oncology, Dana-Farber/Partners Cancer Care, Boston, MA  
2003-2006 Clinical Fellow in Medicine, Brigham and Women's Hospital, Boston, MA  
1997-1998 Laboratory of Jan Vijg, Department of Genetics, Harvard Medical School,  
Beth Israel Deaconess Medical Center, Boston, MA  
1998-1999 Laboratory of Ronald DePinho, Department of Genetics, Harvard Medical School,  
Dana-Farber Cancer Institute, Boston, MA  
2001-2004 Research Associate in the Laboratory of Ronald DePinho  
2004-2007 Postdoctoral Fellow in the Laboratory of Ronald DePinho

### **Licensure and Certification:**

2000- Massachusetts Medical Licensure  
2003- American Board of Internal Medicine, Internal Medicine  
2006- American Board of Internal Medicine, Medical Oncology

### **Academic Appointments:**

2006- Instructor in Medicine, Harvard Medical School, Boston, MA

### **Hospital Appointments:**

2006- Assistant in Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston, MA

**Hospital and Health Care Organization Service Responsibilities:**

2006- Attending Physician in Medical Oncology, Massachusetts General Hospital, Boston, MA

**Professional Societies:**

American Society of Clinical Oncology, Member  
American Association for Cancer Research, Member

**Invited Committees:**

Harvard/ Dana-Farber Cancer Center Scientific Review Committee

**Awards and Honors:**

1996-1997 Dean's List for Academic Excellence, SUNY Buffalo School of Medicine  
1997 John Hartford/American Federation for Aging Research, Medical School Research Fellowship  
1998 Howard Hughes Medical Institute Research Training Fellowship  
1999 Howard Hughes Medical Institute Research Training Fellowship for Medical Students - Continued Support Competition  
2000 Loretta A. Jordan Award for Research of Neoplastic Disease  
2000 Robin Bannerman Memorial Research Award  
2005 PanCAN/ASCO Young Investigator Award  
2007 Howard Hughes Medical Institute Physician-Scientist Early Career Award

**Part 2 Research, Teaching, and Clinical Contributions:**

**Funding Information:**

1997 American Federation for Aging Research  
1998-1999 Howard Hughes Medical Institute Research Training Fellowship  
1998-2000 Howard Hughes Medical Institute Continues Support Program - for the completion of medical studies.  
2004-2006 DFCI Tisch Family Seed Grant for Solid Tumor Research  
2004-2008 Recipient of NIH Clinical Research Loan Repayment Grant  
2006-2008 Co-Investigator; P01: Genetics and Biology of Pancreatic Cancer; Project 1  
2006-2008 Co-Investigator, Samuel Waxman Translation Research Grant: Targeting Stem Cells in Pancreatic Ductal Adenocarcinoma  
2007-2008 DFCI/ HCC GI Spore pilot project. \$75,000  
  
2006-2011 Primary Investigator; K08 CA122835-03: Telomeres, Genomic Instability, and the Roles of p53 and p19Arf in Pancreatic Cancer. \$720,000  
2007-2011 Howard Hughes Medical Institute Physician-Scientist Early Career Award; \$300,000  
2007- co-PI with Nabeel Bardeesy; Genzyme; industry sponsored research project; Preclinical evaluation of TGF-beta blockade in genetically engineered murine pancreatic adenocarcinoma models. \$270,000

- 2008- co-PI with Nabeel Bardeesy; Stromedix; industry sponsored research project; Preclinical evaluation of Integrin alphaVbeta6 blockade in genetically engineered murine pancreatic adenocarcinoma models. \$25,000
- 2008- Amgen; sponsored research grant; A single arm phase 2 trial of panitumumab in Kras wild type cetuximab refractory metastatic colorectal cancer. \$202,000

#### Report of Teaching/Presentations:

- 1998 American Federation for Aging Research Annual Meeting, Seattle WA
- 1999 American Association for Cancer Research Meeting, Cancer Biology and the Mutant Mouse, Keystone, CO
- 1999 Howard Hughes Medical Institute- Research Scholars Program
- 2003 Medical Grand Rounds, Beth Israel Deaconess Medical Center, Boston, MA
- 2006 AACR Mouse Models of Cancer, Poster Presentation
- 2007 PanCAN Summit on Pancreatic Cancer, invited presentation "The role of LKB1 in pancreatic development and neoplasia"
- 2008 Genzyme; Invited seminar speaker
- 2008 Biogen Idec; Invited seminar speaker
- 2008 Vertex Pharmaceuticals; Invited seminar speaker

#### Publications:

##### Original Investigations:

Giese H, Dolle ME, **Hezel A**, van Steeg H, Vijn J. Accelerated accumulation of somatic mutations in mice deficient in the nucleotide excision repair gene XPA. *Oncogene* 1999 Feb 4;18(5):1257-60.

Bardeesy N, Bastian BC, **Hezel A**, Pinkel D, DePinho RA, Chin L. Dual inactivation of the Rb and p53 pathways in RAS-induced melanoma. *Mol Cell Biol* 2001 Mar; 21(6):2144-56.

Bardeesy N, Sinha M, **Hezel A**, Signoretti S, Hathaway N, Sharpless N, Loda M, Carrasco DR, DePinho RA. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. *Nature* 2002 Sep 12;419(6903):162-7.

Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, Tonon G, McNamara K, Marconcini LA, **Hezel A**, El-Bardeesy N, Bronson RT, Sugarbaker D, Maser RS, Shapiro SD, Wong KK. K-ras activation generates an inflammatory response in lung tumors. *Oncogene* 2006 Mar 30;25(14):2105-12.

Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, **Hezel AF**, Feng B, Brennan C, Weissleder R, Mahmood U, Hanahan D, Redston MS, Chin L, Depinho RA. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. *Proc Natl Acad Sci USA* 2006 Apr 11;103(15):5947-52.

Bardeesy N, Cheng K, Berger JH, Chu GC, Pahler J, Olson P, **Hezel AF**, Horner J, Lauwers GY, Hanahan D, and DePinho RA. *Smad4* is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. *Genes Dev* 2006 Nov 15;20(22):3130-46.

Gurumurthy S, **Hezel AF**, Berger JH, Bosenberg MW, and Bardeesy N; LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. *Cancer Res.* 2008 Jan 1;68(1):55-63.

**Hezel A F**, Gurumurthy SG, Granot Z, Chu GC, Bailey G, Dor Y, Bardeesy N, DePinho RA. Pancreatic Lkb1 deletion leads to acinar polarity defects and serous cystic neoplasms. *Mol Cell Biol*. 2008 Apr;28(7):2414-25.

Perera SA, Maser RS, Xia H, McNamara K, Protopopov A, Chen L, **Hezel A**, Kim CF, Bronson RT, Castrillon DH, Chin L, Bardeesy N, Depinho RA, Wong KK. Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. *Carcinogenesis*. 2008 Apr;29(4):747-53.

Wolpin BM, **Hezel AF**, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, and Fuchs CS. Oral mTOR Inhibitor Everolimus (RAD001) in Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer. *JCO*. 2008 *in press*

Kimmelman AC, **Hezel AF**, Aguirre AJ, Zheng H, Paik J, Ying H, Chu GC, Zhang JX, Sahin E, Yeo G, Ponugoti A, Nabioullin R, Deroo S, Yang S, Wang X, McGrath JP, Protopopova M, Ivanova E, Zhang J, Feng B, Tsao MS, Redston M, Protopopov A, Xiao Y, Futreal PA, Hahn WC, Klimstra DS, Chin L, DePinho, RA. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. *in review*.

Reviews, editorials, letters:

**Hezel AF**, Bardeesy N, Maser RS. Telomere induced senescence: end game signaling. *Curr Mol Med* 2005 Mar;5(2):145-52. Review.

**Hezel AF**, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. *Genes Dev* 2006 May 15;20(10):1218-49. Review.

Chu GC, Kimmelman AC, **Hezel AF**, and DePinho RA. Stromal Biology of Pancreatic Cancer. *J Cell Biochem* 2007 Jan 31. Review.

**Hezel AF**, Ryan DP. Emerging therapies for colorectal cancer. *Expert Opin Investig Drugs*. 2007 Jun;16(6):867-76. Review.

**Hezel AF**, Zhu AX. Systemic therapy for biliary tract cancers. *Oncologist*. 2008 Apr;13(4):415-23. Review.

**Hezel AF**, Bardeesy N. Lkb1; linking cell structure and tumor suppression. *Oncogene* 2008 *in press* Review.